- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Episode 14 - Conclusion: Final Thoughts Concerning Immunotherapy
During this segment, the panelists share their final insights about the future of immunotherapy.
Jeffrey Weber, MD, PhD, believes that treating patients with immunotherapy will benefit all parties involved in healthcare and does not fear the shift toward “Obamacare.” Dr Weber explains that even as treatment decisions become more data driven, he does not believe that much will change in the way that great physicians consider and treat their patients.
Daniel J. George, MD, is equally excited for the future of immunotherapy, although he is concerned that there is currently an educational lag when considering the different factors associated with immunotherapy. However, he does believe that as immunotherapy becomes a more common treatment modality for fields other than oncology, this barrier will be overcome.
Michael Kolodziej, MD, concludes the discussion by explaining that immunotherapy is in its “golden age.” Furthermore, Dr Kolodziej believes that healthcare reform offers the oncology field, pharmaceutical industry, and the entire healthcare enterprise the opportunity to redefine their roles in positive ways.
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
